Pharmafile Logo
Pharmafocus logo
Advanced Search

lifitegrast

Showing 8 posts of 8 posts found.

shire_image_4

FDA to decide on Shire blockbuster hopeful

February 8, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast

The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …

News
shire_image

Shire tries again with lifitegrast dry eye FDA application

January 25, 2016
Manufacturing and Production, Sales and Marketing FDA, Shire, dry eye disease, lifitegrast

Shire has resubmitted its New Drug Application (NDA) to the US FDA for its rejected dry eye syndrome drug lifitegrast. …

News
Ikervis

New treatments to boost dry eye drug market – if approved

November 5, 2015
Sales and Marketing Allergan, Ikervis, Restasis, Shire, cyclosporine, dry eye disease, dry eye syndrome, lifitegrast

The global market for treatments for dry eye syndrome will double in value to an estimated $4.6 billion by 2024, …

News
eye

Featured market report: Summary of dry eye syndrome

November 5, 2015
dry eye disease, dry eye syndrome, lifitegrast

This report provides the current prevalent population for dry eye syndrome across seven major markets.It includes data for the USA, …

Feature
Shire image

New Phase III data puts Shire’s lifitegrast back on track for 2016 launch

October 27, 2015
Research and Development Shire, dry eye disease, lifitegrast

Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …

News
Flemming Ornskov

Shire’s dry eye treatment gets a no – for now

October 19, 2015
Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast

Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …

News
Shire building

Shire in $300m Foresight acquisition

August 4, 2015
Manufacturing and Production, Research and Development, Sales and Marketing FST-100, Foresight Biotherapeutics, Shire, conjunctivitis, dry eye, lifitegrast, pink eye

Shire has acquired Foresight Biotherapeutics for $300 million, as it looks to build its presence in eye diseases. The acquisition …

News
Shire image

Shire gets FDA boost – but suffers trial setback

April 10, 2015
Research and Development, Sales and Marketing FDA, Shire, algs, lifitegrast, shp625

Shire has achieved mixed results in its attempts to get regulatory approval for two new treatments – bagging a priority …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024